Announcements Trials

Browse Landscape

Phase

Status

Recruiting 18 Unknown 9 Not yet recruiting 9 Completed 8 Active not recruiting 8 Terminated 6 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Mesothelioma, Malignant 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Anus Neoplasms 1

Interventions

Carboplatin 33 Pemetrexed 25 Cisplatin 23 Paclitaxel 20 Radiotherapy 16 Docetaxel 16 Gemcitabine 15 durvalumab 14 Radiosurgery 14 pembrolizumab 13 Nivolumab 13 Erlotinib Hydrochloride 10 Taxes 8 atezolizumab 7 Magnetic Resonance Spectroscopy 7 Drug Therapy 6 Cyclophosphamide 6 Bevacizumab 6 Platinum 5 Gefitinib 5 130-nm albumin-bound paclitaxel 5 Etoposide 4 Biopsy 4 Albumin-Bound Paclitaxel 4 1,2-diaminocyclohexaneplatinum II citrate 4 spartalizumab 3 sotorasib 3 poly ICLC 3 capmatinib 3 Surveys and Questionnaires 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoma, Non-Small-Cell Lung × tislelizumab × Clear all

NCT05791097 2023-07-24

AdvanTIG-306

Novartis

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡